Givinostat
- Generic Name
- Givinostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H27N3O4
- CAS Number
- 497833-27-9
- Unique Ingredient Identifier
- 5P60F84FBH
- Background
Givinostat has been used in trials studying the treatment of Polycythemia Vera, Juvenile Idiopathic Arthritis, Duchenne Muscular Dystrophy (DMD), Chronic Myeloproliferative Neoplasms, and Polyarticular Course Juvenile Idiopathic Arthritis.
- Associated Conditions
- -
- Associated Therapies
- -
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Italfarmaco
- Target Recruit Count
- 220
- Registration Number
- NCT06093672
- Locations
- 🇺🇸
VA Puget Sound Health Care System - NAVREF - PPDS, Seattle, Washington, United States
🇺🇸The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Italfarmaco
- Target Recruit Count
- 138
- Registration Number
- NCT05933057
- Locations
- 🇧🇪
Universitaire Ziekenhuizen Leuven, Leuven, Belgium
🇨🇦British Columbia Children's Hospital, Vancouver, British Columbia, Canada
🇨🇦The University of Western Ontario - Children's Health Research Institute, London, Ontario, Canada
Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3)
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Italfarmaco
- Target Recruit Count
- 8
- Registration Number
- NCT05860114
- Locations
- 🇵🇹
Hospital da Prelada, 3rd Floor & East Wing 4th Floor Rua Sarmento de Beires, Porto, Portugal
The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2)
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Italfarmaco
- Target Recruit Count
- 20
- Registration Number
- NCT05845567
- Locations
- 🇵🇹
Hospital da Prelada, 3rd Floor & East Wing 4th Floor Rua Sarmento de Beires, Porto, Portugal
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- First Posted Date
- 2017-12-14
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Italfarmaco
- Target Recruit Count
- 206
- Registration Number
- NCT03373968
- Locations
- 🇮🇹
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, UOS di Neurologia Pediatrica, Milan, Italy
🇫🇷CHU de Nantes - Hotel-Dieu - Hopital Nord Laennec, rez-de-chausse haut ail Ouest, Nantes, France
🇬🇧The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust, Gobowen, United Kingdom
Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Becker Muscular Dystrophy
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Italfarmaco
- Target Recruit Count
- 51
- Registration Number
- NCT03238235
- Locations
- 🇳🇱
Leiden University Medical Center LUMC, Leiden, Netherlands
🇮🇹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, UOS, Milan, Italy
Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
- First Posted Date
- 2016-08-02
- Last Posted Date
- 2023-02-02
- Lead Sponsor
- Italfarmaco
- Target Recruit Count
- 179
- Registration Number
- NCT02851797
- Locations
- 🇺🇸
Neuromuscular Research Center UC Davis Department of Physical Medicine and Rehabilitation, Davis, California, United States
🇺🇸Rady Children's Hospital center - UCSD Department of Neuroscience, San Diego, California, United States
🇺🇸Child Health Research Institute - Department of Pediatrics, Gainesville, Florida, United States
A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera
- First Posted Date
- 2013-07-17
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Italfarmaco
- Target Recruit Count
- 48
- Registration Number
- NCT01901432
- Locations
- 🇫🇷
Hôpital Saint-Louis (AP-HP), Centre Investigations Cliniques, Paris Cedex 10, France
🇵🇱Uniwersyteckie Centrum Kliniczne, Gdansk, Poland
🇮🇹Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, BG, Italy
Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2013-01-07
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Italfarmaco
- Target Recruit Count
- 90
- Registration Number
- NCT01761968
- Locations
- 🇩🇪
Universitaetsklinikum Freiburg, Innere Medizin I - Haematologie und Onkologie, Freiburg, Germany
🇮🇹Azienda Ospedaliero-Universitaria Policlinico Consorziale, Bari, Bari, BA, Italy
🇩🇪Charite Research Organization GmbH, Berlin, Germany
A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMD
- First Posted Date
- 2013-01-04
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Italfarmaco
- Target Recruit Count
- 20
- Registration Number
- NCT01761292
- Locations
- 🇮🇹
IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy
🇮🇹Azienda Ospedaliera Universitaria Policlinico G. Martino, Messina, Italy
🇮🇹Ospedale Pediatrico Bambino Gesù, Rome, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.